908 Devices Inc. is democratizing chemical analysis by way of mass spectrometry.

We make products ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices.  These purpose-built and user-centric devices serve a range of industries including safety and security, oil & gas, life sciences and other applied markets.

Come on in.

Take a stroll through our full-scale manufacturing facility and see where your HPMS device is crafted with care.

Great things are happening.

Get a firsthand account of HPMS technology, M908, and the excitement of things to come.

Leadership Team & Founders

  • Dr. Kevin J. Knopp

    Dr. Kevin Knopp is a co-founder & CEO of 908 Devices Inc. An experienced high-tech entrepreneur, Kevin co-founded Ahura Scientific in 2002, and was Senior Vice President overseeing Operations, R&D and Safety and Security Sales through Ahura’s acquisition by Thermo Fisher Scientific in 2010, where he continued as Vice-President and Site Leader of the Portable Optical Analysis division. Kevin served as an independent board member for Crystal IS until its acquisition by Asahi-Kasei. He earned B.S.E.E from Boston University, M.S.E.E, and Ph.D. degrees in Optics from the University of Colorado. Kevin is an inventor on more than 20 US patents, is an author on more than a dozen refereed publications, and his products have received R&D 100, Business Week IDEA, GSN, CPhI Gold, Cygnus, and Frost & Sullivan awards.

  • Dr. Christopher D. Brown

    Dr. Chris Brown is a co-founder, VP and CTO of 908 Devices Inc. Prior to founding 908 Devices, Chris was a platform architect at Apple in California leading investigations into future-gen hardware/software technologies. Before joining Apple, he headed Product Development and Engineering at Ahura Scientific and later Thermo Fisher Scientific, which acquired Ahura Scientific in 2010. Joining Ahura in 2004 he established the company’s core embedded analytics and chemometrics capability, led product and market development for the pharmaceutical/industrial vertical, and established the international applications, and scientific support teams. Prior to Ahura, Chris held several senior leadership roles at InLight Solutions developing multiple clinical, in-vivo and non-invasive biodiagnostic products across a range of imaging and spectroscopic modalities. He has published some 150 papers and presentations, and more than 30 granted/pending patents. Chris received his B.Sc. from Brandon University and Ph.D. in Chemistry from Dalhousie University where he developed chemometric techniques for mass spectrometry and chromatography.

  • Dr. Christopher J. Petty

    Dr. Chris Petty is a co-founder and VP of Business Development and Marketing with 908 Devices. Chris is an executive with over 21-years experience in the analytical instrumentation industry. Chris has been responsible for development of new markets and market expansions introducing product platforms in numerous high growth acquired businesses at Thermo Fisher Scientific. Chris defined and implemented growth strategies, stood up new vertical segments and was responsible for full P&L as VP and General Manager for both Ahura Scientific and Polychromix businesses. Prior, Chris successfully executed growth and expansion strategies in the Life Science sector as VP/GM for Thermo Fisher’s NanoDrop business, a high-growth innovator focused on DNA, RNA and protein measurements. As Director of Product Development, for Thermo he led the development and introduction of numerous market-leading Raman and FTIR platforms. He has more than 25-refereed papers and conference presentations, has won R&D 100 and Frost & Sullivan awards for his products, and an American Marketing Association award for interactive promotional campaigns. Chris received a Ph.D. in Chemistry and B.Sc. in Physics from Southampton University in the UK with industrial sponsorship from PerkinElmer.

  • John Kenneweg

    John Kenneweg is Vice President & GM of our Safety & Security Vertical. A veteran of the industry, John has over 17 years of successful sales and marketing experience, directing sales and business development efforts for innovation leaders such as Draeger, Ahura Scientific and Thermo Fisher Scientific. Most recently, John held the position of Director of Federal Government Programs at Thermo Fisher Scientific’s Portable Analytical Instrument business where he generated significant growth across multiple product platforms. He was part of the original Ahura Scientific sales team that successfully launched the first handheld Raman and FTIR spectrometers. He has been successful in developing markets for multiple new technologies and solutions to the safety and security market to include federal agencies, military organizations and civilian emergency responders. John graduated from West Virginia University and served in the United States Marine Corps.

  • Michael Jobin

    Mr. Michael Jobin is a co-founder of 908 Devices and leads mechanical engineering and design efforts. He has 20 years of experience in instrumentation, medical and consumer markets. As Director of Engineering at Altitude, Inc. a leading product development firm, he led design and mechanical engineering on numerous groundbreaking handheld instruments and tools for Ahura Scientific, Niton Corporation and DeWALT. Through this work, Michael has been instrumental in the successful transition of multiple technologies including Raman, FTIR and XRF techniques from laboratory to field use. Michael was the co-founder and Chief Technology Officer of MicroBiosciences, a Boston based startup developing microfluidics instruments for medical research. Michael holds 12 patents, and has several applications pending. He earned a BS in Mechanical Engineering and a BFA in Industrial Design from the University of Michigan.

  • Steve Araiza

    Mr. Steve Araiza is a co-founder of 908 Devices and serves as Director of Software. He has over 15-years of software engineering and architecture experience. He has delivered products in such diverse applications as medical devices, and distributed software systems however, he has particular expertise in all aspects of handheld analytical tools. Steve has led design and implementation of the software architecture for multiple analytical handheld product platforms. This work spanned design, architecture, embedded systems and user interface from concept through implementation. In addition, Steve has consulted on and delivered software solutions for over 25 companies including Ahura Scientific, Adaptive Optics, Agilent, Light Lab Imaging (now St. Jude Medical), Raytheon and Philips Medical. Steve earned his B.S.E.E from California State University.

  • Andy Bartfay

    Mr. Andy Bartfay is a co-founder of 908 Devices and serves as Director of Hardware Development. His 25 years of electronics design experience spans a diverse range of applications and technologies. In particular, he has significant experience with integrated systems for handheld and portable platforms and has been responsible for the complete electronic design of several successful handheld products. His specific capabilities include chip and board-level design, high speed digital and mixed signal design, embedded computers and firmware, high reliability and mil-spec systems, all aspects of electronic product manufacturing, and agency approval testing. Andy has supplied design services or complete products to a broad range of customers including Perkin Elmer, Ahura Scientific, Philips Medical, Boeing, Disney, Lockheed and the US government. Andy earned his B.S. in Electrical Engineering from the University of Rochester and has two patents granted or pending.

  • Dr. Scott Miller

    Dr. Scott Miller is a co-founder of 908 Devices and serves as Director of Mass Spectrometer Engineering, leading applications and system integration efforts. Prior to joining 908 Devices, Scott was Principal Development Engineer at Ahura Scientific and at Thermo Fisher Scientific following acquisition. He led several multi-million dollar government-funded R&D projects. These projects were focused on development of portable, easy-to-use analytical instruments for chemical and biological detection and identification. Prior to joining Ahura Scientific, Scott was Principal Scientist at BioProcessors Corp. where he developed automated, microscale cell culture systems. He has authored over a dozen peer-reviewed articles and has several patents pending. Scott received his Ph.D. in Physical Chemistry from Northwestern University and held a postdoctoral position at MIT.

  • Dr. Kevin McCallion

    Kevin McCallion joins 908 Devices as Director of Component Engineering. Kevin has a successful track record in technical management of complex, high reliability products. He has extensive experience in new product development, implementation of high component density product designs and product assembly techniques for high technical function products. Kevin served as VP of Engineering for TeraDiode, a developer of compact, high efficiency laser sources. Previously, Kevin was a co-founder and VP of Product Development at Azna LLC, implementing novel, high-speed diode lasers for long haul transmission. Earlier in his career, Kevin held senior technical management positions at Nortel Networks and CoreTek, Inc. Kevin received BEng (1st Hons), MSc and PhD degrees in Electrical Engineering and Optoelectronics from the University of Strathclyde in the UK. Kevin is an inventor on more than 30 US patents and is author on numerous publications.

  • Joseph H. Griffith IV

    Mr. Joe Griffith joins 908 Devices as Chief Financial Officer supporting the development of strategic business plans and financial metrics. Joe brings a 17-year management background in corporate and operational finance, accounting and administration. Most recently he served as Chief Financial Officer for PerkinElmer’s Life Science division. Previously, Joe served in numerous roles for Caliper Life Sciences including Chief Accounting Officer, VP of Finance and Corporate Controller. Joe achieved a BS in Accounting from Villanova University and holds Certified Public Accountant status in Pennsylvania.

  • Dr. J. Michael Ramsey

    Dr. J. Michael Ramsey is the Goldby Distinguished Professor of Chemistry at the University of North Carolina – Chapel Hill. Dr. Ramsey is also the director of the UNC Center for Biomedical Microtechnologies, a center focused on fostering collaborations between medical researchers or clinicians and developers of microtechnologies for enhancing access to biological information. His present research interests include highly miniaturized mass spectrometry, micro- and nanofluidics, and single molecule DNA sequencing, single cell assays and point-of-care clinical diagnostic devices. Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), later renamed Caliper Life Sciences and acquired by PerkinElmer in late 2011 for $650M. Caliper is the leading commercial supplier of microfluidic technologies; tools primarily used in the pharmaceutical and biotechnology industries. Dr. Ramsey is also the scientific founder of 908 Devices Inc. and serves as chair of the Scientific Advisory Board.

  • Dr. Trent Basarsky

    Dr. Trent Basarsky is the Vice President & GM of 908 Device’s Life Science Vertical. Trent is a marketing and business executive with more than 20 years of experience in the life sciences sector. Prior to joining 908 Devices, Trent was the Chief Business Officer at Zephyrus Biosciences, the developers of a single cell western platform, which was acquired by BioTechne in 2016. Previously Trent was the VP of Corporate Development at ProteinSimple, a company focused on protein analysis instrumentation, where his responsibilities in corporate development, marketing and intellectual property helped grow the company to over $55M in revenue prior to the successful sale of the company for $300M. Trent served as the Director of Corporate Development at Codexis, a cleantech company focused on next-generation biofuels and pharmaceutical manufacturing. Before joining Codexis, he was Director of Corporate Development at Molecular Devices and helped grow the business to more than $180M prior to the sale of the company for over $600M. He also held positions in marketing, product management, business development and intellectual property at Axon Instruments, which was acquired by Molecular Devices. Trent holds a Ph.D. in Neuroscience from Iowa State University, a B.Sc. in Zoology from the University of Alberta, and is a registered patent agent. He enjoys endurance mountain bike racing, playing competitive hockey, and golf.

Departments

  • Applied Science & Chemistry

    We turn complicated data into actionable knowledge. Our team of scientists and analytical chemists are optimizing technologies central to our products. Designing experiments that define future capabilities. Pushing the boundaries of current performance standards. Incorporating new analytical techniques for future product development. And integrating leading-edge analytical techniques with user experience for sought after ‘push button, get answer’ tools.

    Our laboratories are buzzing with new applications development. Performance standards are high and the possibilities with HPMS are endless.

    Scott Miller, Director of MS Engineering

  • Component Engineering

    We make smaller parts for smaller products. Each component we design and build is held to exacting standards for performance, serviceability and repeatability. Using state-of-the-art machine tools and rigid quality control processes, our vacuum pumps, MS cores and electronics boards are developed for reliability by our component engineering team.

    It’s the disciplined reliability built into our HPMS systems that make our products unique. Test. Retest. Then test again. This is how we ensure quality of the form, fit, and functionality of each component.

    Kevin McCallion, Director of Component Engineering

  • Electrical Design

    Our electrical design is the nexus between performance and engineering. The demand for smaller, lighter weight products with increased functionality and advanced features pose a challenge for electrical design. From PCB development and housing design through the creation of cooling systems – everything must shrink, except performance. We take an integrated approach that effectively merges electrical, mechanical and industrial design at every step of the development process to maximize performance – no matter how small the products get.

    The engineering of a bold new product benefits greatly from a top-down and bottom-up design approach. Considering all aspects in unison guides and empowers a design process that achieves best-in-class electronics.

    Andy Bartfay, Director of Electrical Design

  • Product Development

    Our designs are driven by function. We blend technical, physical and aesthetic properties to deliver truly useful integrated solutions that solve real-world challenges. The allure of physical design coupled with distinguished performance and functionality add significant credibility to our product offering. We engage customers at every stage of the development process. As a result each feature is intentional to meet their unmet need.

    The end goal is important to realize early in the product development process. We work to make complex analysis simple, and strive for jaw-dropping customer reactions.

    Michael Jobin, Director of Product Development

  • Software & Algorithms

    Our approach to software began with the end in mind. The interface would be slick, simple and unambiguous. Discoverable features would provide dynamic control over mass spec analysis. Results would require no interpretation. The outcome is a truly holistic experience. Our software strikes a fine balance between structure and flexibility. This means providing peak performance while staying light on our feet to adapt to new customer requirements. Under the hood, software automation and on-board analytics make data work for you, rather than you working to understand data. We strive to provide robust, reliable answers with defined true and false positive rates so there is no question.

    Great technology is futile if people don’t know how to interact with it. We dwell on the user experience and reliability of answers.

    Steve Araiza, Director of Software Development

Governance & Investors

  • ARCH Venture Partners
  • Casdin Capital
  • Keith L. Crandell
  • Jay Flatley
  • Kevin Hrusovsky
  • In-Q-Tel
  • Dr. James W. Jorgenson
  • Douglas Kahn
  • Dr. Kevin J. Knopp
  • Martin D. Madaus, PhD
  • Dr. Alan G. Marshall
  • Paul Meister
  • Manuel O. Méndez
  • Dr. J. Michael Ramsey
  • Razor’s Edge Ventures
  • Stephen V. Reeves
  • Dr. Nicolas H. Roelofs
  • Saudi Aramco Energy Ventures
  • Schlumberger
  • Mark Spoto
  • Artur Stankiewicz
  • Corey Steffek
  • University of Tokyo Edge Ventures
  • Dr. Daryoosh Vakhshoori
  • Dr. David R. Walt
  • ARCH Venture Partners

    ARCH Venture Partners invests in the development of seed and early stage technology companies that have the potential to grow rapidly into successful businesses. ARCH invests primarily in companies co-founded with leading scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences, physical sciences, and information technology. ARCH Ventures enjoys special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH currently manages seven funds totaling nearly $1.5 billion and has invested in the earliest venture capital rounds for more than 120 companies. ARCH investors include major corporations, pension funds, endowment funds, financial institutions, and private investors. For more information visit www.archventure.com.

  • Casdin Capital

    Casdin Capital is an investment firm founded in 2011 with offices in New York and San Diego. Our firm actively seeks out life science innovation that disrupts the diagnostic, drug development and industrial biotechnology business models, dramatically improving quality of life and generating substantial long term investment returns along the way.

    The firm’s investment philosophy is rooted in a conviction that business success is defined by the people managing the business. Our approach is to leverage our deep domain expertise and extensive proprietary research process to identify and invest in great people targeting large market opportunities.

    Long-term capital appreciation is the product of patience and persistence (investment conviction). As investors awaken to an opportunity and capital begins to move in its direction, its momentum takes a long time to be spent, resulting in dramatic appreciations of value. We position ourselves to capitalize on these long-term opportunities in the life science sector.

  • Keith L. Crandell

    Keith Crandell is a co-founder and a Managing Director of ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory.

    Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, and Ciespace. Mr. Crandell also serves as a director of the Illinois Venture Capital Association.

    Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

  • Jay Flatley

    Jay Flatley has served as CEO and director of Illumina, Inc. since October 1999. He drives strategic vision for the company and manages its commercial and corporate functions. With the company’s initial success in genotyping and subsequent expansion into whole-genome sequencing, diagnostics and informatics, sales grew from $1.3 million in 2000 to more than $1.4 billion in 2013. Under Mr. Flatley’s leadership, the company has launched over 60 major products, acquired several new technologies, and entered multiple markets in the research, applied, and clinical arenas. Prior, Mr. Flatley was co-founder, President, and CEO of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.

  • Kevin Hrusovsky

    E. Kevin Hrusovsky was appointed President, Life Sciences and Technology, PerkinElmer following PerkinElmer’s acquisition of Caliper (CALP). Kevin served as CEO of Caliper Life Sciences from July 2003, when Zymark Corporation was acquired by Caliper. With a strong commercialization and external focus, Caliper was transformed into a leading edge personalized medicine / health technology company. Its market value grew the fastest in the entire life sciences landscape during the period 2009 – 2011. CALP was sold in late 2011 for $650M cash. Prior to the acquisition, he served as President and CEO of Zymark. Under Kevin’s leadership, Zymark was transformed from a custom robotics job shop into a leading life sciences tools and informatics company. Prior to this, Kevin was Director of International Business, Agricultural Chemical Division, and President of the Pharmaceutical Division, for FMC Corporation. From 1983 to 1992, he held several management positions at E.I. DuPont de Nemours, including North American Sales and Marketing Head, Teflon.

    Hrusovsky currently sits on the Board of 908 Devices, the Educational Board of the Massachusetts Biotech Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the JALA Editorial Board, and the Strategy Committee of Children’s Hospital Boston. He formerly served on the boards of SeraCare, Caliper Life Sciences, Xenogen Corporation and Alliant Medical Technology. Hrusovsky received an Honorary Doctorate degree from Framingham State University for contributions in life sciences. He received his B.S. in Mechanical Engineering from Ohio State University and an M.B.A. from Ohio University.

  • In-Q-Tel

    In-Q-Tel is the not-for-profit, strategic investment firm that works to identify, adapt, and deliver innovative technology solutions to support the missions of the U.S. Intelligence Community. Launched in 1999 as a private, independent organization, IQT’s mission is to identify and partner with companies developing cutting-edge technologies that serve the national security interests of the United States. Working from an evolving strategic blueprint defining the Intelligence Community’s critical technology needs, IQT engages with entrepreneurs, startups, researchers, and investors to deliver technologies that provide superior capabilities for the CIA and broader Intelligence Community. For more information, visit www.iqt.org.

  • Dr. James W. Jorgenson

    Dr. James W. Jorgenson is the William Rand Kenan, Jr. Distinguished Professor of Chemistry at the University of North Carolina in Chapel Hill. He was Chair of the UNC Chemistry Department from 2000 to 2005. Professor Jorgenson is one of the inventors of capillary electrophoresis (CE), and the originator of ultra-high pressure liquid chromatography (UHPLC). His current research interests include ultra-high pressure liquid chromatography, multidimensional separations, microscale separations coupled to mass spectrometry, and the application of this technology to proteomics and metabolomics.

  • Douglas Kahn

    Douglas Kahn is Executive Chairman of Tetragentics, Inc., an innovative life science company that developed a new technology for drug discovery. Mr. Kahn was previously Chairman & CEO of Ahura Scientific, Inc., the world’s leader in the design and manufacture of advanced ultra-compact spectroscopic instruments for safety, security and pharmaceutical applications. Prior to joining Ahura Scientific, Mr. Kahn served as President and CEO of PanAmSat Corporation, an international provider of satellite communications services and operator of a global fleet of 21 geostationary satellites. He also served as Chairman and CEO of Easel Corporation, a venture capital financed software company which he led through ten years of growth and a successful IPO. Mr. Kahn holds a BS in Operations Research and Industrial Engineering from Cornell University and an MBA from Stanford University.

  • Dr. Kevin J. Knopp

    Dr. Kevin Knopp is a co-founder & CEO of 908 Devices Inc. An experienced high-tech entrepreneur, Kevin co-founded Ahura Scientific in 2002, and was Senior Vice President overseeing Operations, R&D and Safety and Security Sales through Ahura’s acquisition by Thermo Fisher Scientific in 2010, where he continued as Vice-President and Site Leader of the Portable Optical Analysis division. Kevin served as an independent board member for Crystal IS until its acquisition by Asahi-Kasei. He earned B.S.E.E from Boston University, M.S.E.E, and Ph.D. degrees in Optics from the University of Colorado. Kevin is an inventor on more than 20 US patents, is an author on more than a dozen refereed publications, and his products have received R&D 100, Business Week IDEA, GSN, CPhI Gold, Cygnus, and Frost & Sullivan awards.

  • Martin D. Madaus, PhD

    Dr. Martin D. Madaus, Chairman and Chief Executive Officer at Ortho-Clinical Diagnostics, Inc. (OCD), has more than 25 years of experience in the diagnostics and life science industries.
    Prior to joining OCD, Dr. Madaus served as Executive Chairman of Quanterix Corporation, and as Senior Healthcare Advisor to the Carlyle Group.

    He was Chairman, President and Chief Executive Officer of Millipore Corporation (NYSE: MIL) from January 2005 to July 2010. In addition, Dr. Madaus was President and Chief Executive Officer of Roche Diagnostics Corporation from 2000 to 2004, where he served as head of North American Operations. Prior to that, he served as Vice President of Business Development for Roche Molecular Diagnostics, and served as the President of Roche Diagnostics Canada.

    Dr. Madaus started his career in the Diagnostics Industry in 1989 at Boehringer Mannheim, Germany and served in various product management, marketing and general management roles in Germany, the United States and Canada.

    Dr. Madaus has extensive public and private company board experience and currently serves on the board of Mettler-Toledo International Inc (NYSE: MTD) and Quanterix Corporation (private). In addition, he served as a Director of Covidien PLC (NYSE: COV), Millipore (NYSE:MIL), PPD International (private) and Predictive Bioscience (private).
    Dr. Madaus received a Doctor of Veterinary Medicine degree from the University of Munich in Germany and a PhD in Veterinary Medicine from the Veterinary School of Hanover in Germany.

  • Dr. Alan G. Marshall

    Dr. Alan G. Marshall is the Robert O. Lawton Professor of Chemistry and Biochemistry and Director of the Ion Cyclotron Resonance (ICR) Program at Florida State University. He co-invented and leads the continuing development of Fourier transform ICR mass spectrometry. His current research spans FT-ICR instrumentation development, fossil fuels and environmental analysis, and mapping the primary and higher-order structures of biological macromolecules and their complexes. He is a former President of the American Society for Mass Spectrometry, and serves on several editorial boards. He has published 4 books, 7 patents, and 570 refereed journal articles. His papers have been cited more than 24,500 times.

  • Paul Meister

    Paul Meister is President of MacAndrews & Forbes Incorporated. He is also co-founder of Liberty Lane Partners, LLC, a private investment company with investments in healthcare, technology, and distribution-related industries and Perspecta Trust, a trust company that provides trust and investment services. Mr. Meister previously served as Chairman and CEO of inVentiv Health, a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries.

    Prior to that, he served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo. During his tenure as an executive officer of Fisher Scientific, from 1991 to 2006, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively as operations grew from two countries to 27 and sales expanded into 140 countries worldwide.

    Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company.

    Mr. Meister holds a Bachelor of Arts degree from the University of Michigan and an MBA from Northwestern University. He is a director of LKQ Corporation, Scientific Games Corporation, Quanterix Corporation; co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.

  • Manuel O. Méndez

    Manuel O. Méndez is Executive Vice President and General Manager of Americas Commercial Operations at bioMérieux. Prior to joining bioMérieux in 2010, Mr. Méndez served in various domestic and international executive leadership roles at Abbott Laboratories, Thermo Fisher Scientific, and Orasure Technologies. From 2007 to 2009, he served as Director of Global Sales, Marketing and Business Development at Thermo Fisher Scientific. Prior to that, he spent over two years as General Manager BENELUX (Belgium, Netherlands, and Luxembourg) Diagnostics Division, a division of Abbott Laboratories, based in Belgium. From 2003 to 2005, he served as President & GM of Abbott Korea.

    Mr. Méndez has served as a member of the Board of Directors at VillageCare, a community-based, not-for-profit organization in New York City that is dedicated to serving senior persons living with HIV/AIDS as well as individuals in need of continuing care and rehabilitation services.

    He received a B.S. degree in Biomedical Engineering from Boston University and an MBA degree from Northwestern University Kellogg School of Management.

  • Dr. J. Michael Ramsey

    Dr. J. Michael Ramsey is the Goldby Distinguished Professor of Chemistry at the University of North Carolina – Chapel Hill. Dr. Ramsey is also the director of the UNC Center for Biomedical Microtechnologies, a center focused on fostering collaborations between medical researchers or clinicians and developers of microtechnologies for enhancing access to biological information. His present research interests include highly miniaturized mass spectrometry, micro- and nanofluidics, and single molecule DNA sequencing, single cell assays and point-of-care clinical diagnostic devices. Dr. Ramsey is the sole scientific founder of Caliper Technologies (NASDAQ:CALP), later renamed Caliper Life Sciences and acquired by PerkinElmer in late 2011 for $650M. Caliper is the leading commercial supplier of microfluidic technologies; tools primarily used in the pharmaceutical and biotechnology industries. Dr. Ramsey is also the scientific founder of 908 Devices Inc. and serves as chair of the Scientific Advisory Board.

  • Razor’s Edge Ventures

    Razor’s Edge is a venture capital fund founded by a group of distinguished entrepreneurs and executives from the national security industry. Razor’s Edge invests in, and partners with, private technology companies serving the national security market exclusively or in combination with other commercial markets.
    Razor’s Edge has a unique understanding of the national security community’s strategic priorities and works tirelessly to identify and deliver disruptive technologies capable of advancing critical mission needs. We vet technology every day under challenging circumstances where the stakes are high and schedules are unforgiving. The goal of Razor’s Edge is easily summarized but demands a broad cross-section of skills to attain: We will help innovative companies rapidly deliver unique capabilities to the Government customers who need them. For more information visit www.razorsvc.com.

  • Stephen V. Reeves

    Steve Reeves is a highly accomplished senior executive and an internationally recognized expert on Chemical and Biological Defense and Defense Acquisition. Experienced in leading and managing large, diverse, and global, multi-billion dollar organizations, Reeves established, and for seven years led the first Department of Defense Joint Program Executive Office. Working with the White House, other cabinet departments and the Congress, Reeves was instrumental in developing national policy guidance for delivering both defense systems and medical devices and pharmaceuticals to U.S. Forces, international and coalition partners, and for Homeland Security as well as broader policy guidance for national chemical and biological defense and medical systems.

    Also an expert in Defense Acquisition, Reeves has lectured extensively on Defense Acquisition both internationally and domestically, including at the National Defense University, and the Defense Acquisition University including for three years as the capstone speaker for the Senior Executive Course. Reeves was selected as the Army’s Project Manager of the Year, is a two-time winner of the Department of Defense David Packard Award for Acquisition Excellence, and received the U.S. Vice President’s Hammer Award for Innovation in Defense Contracting.

  • Dr. Nicolas H. Roelofs

    Dr. Nicolas H. Roelofs, Ph.D., has more than 19 years of experience in the Life Sciences and Diagnostics industry, most recently as Senior Vice President and President of the Life Sciences Group at Agilent Technologies Inc. Dr. Roelofs joined Agilent from Bio-Rad where he served as Group Operations Officer of the protein separations and analysis, genomics and food science business. Previously he served as SVP of marketing & Asian sales at Stratagene Corp. and went on to lead the company as Chief Operating Officer responsible for all commercial operations. He also served as a Business Unit Director at Applied Biosystems. Dr. Roelofs received his Ph.D. in Organic Chemistry from the University of Nevada, Reno and an M.S. in Organic Chemistry from the University of Iowa.

  • Saudi Aramco Energy Ventures

    SAEV is the corporate venturing subsidiary of the Saudi Arabian Oil Company (Saudi Aramco), the world’s leading fully integrated energy and petrochemical enterprise. Headquartered in Dhahran with offices in North America and Europe, SAEV’s mission is to invest globally in start-ups and high growth companies with technologies of strategic importance to its parent, Saudi Aramco.

  • Schlumberger

    Schlumberger (NYSE:SLB) is the world’s leading supplier of technology, integrated project management and information solutions to customers working in the oil and gas industry worldwide. Employing approximately 120,000 people representing over 140 nationalities and working in more than 85 countries, Schlumberger provides the industry’s widest range of products and services from exploration through production. Schlumberger Limited has principal offices in Paris, Houston and The Hague, and reported revenues from continuing operations of $41.73 billion in 2012. For more information, visit www.slb.com

  • Mark Spoto

    At Razor’s Edge, Mr. Spoto is responsible for the fund’s day-to-day business operations. His primary responsibilities include the identification and evaluation of investment opportunities, market and industry analyses, deal structuring, fundraising, and LP relations, as well as support of and advice to Razor’s Edge portfolio companies. Prior to joining Razor’s Edge, Mr. Spoto was a partner in the Reston, Virginia office of Cooley LLP, a national law firm. He worked with many emerging and high growth technology companies and investment funds, and his practice focused on mergers and acquisitions, venture capital, private equity and public securities offerings, and general corporate representation. His operating company clients were engaged in high-growth industry sectors including software, government contracts, aerospace/defense, telecommunications, and media. From 2008-2011, Chambers USA named Mr. Spoto to its list of America’s Leading Lawyers for Business, and in 2009, he was selected by The Legal 500 as a leading lawyer in the fields of venture capital and emerging companies. Prior to practicing law, Mr. Spoto was an aerospace engineer, working on the Air Force Titan IV rocket program for McDonnell Douglas Space Systems Company. He holds a B.S. in Aerospace Engineering from Boston University and a J.D. from Georgetown University Law Center.

  • Artur Stankiewicz

    Artur Stankiewicz is Schlumberger’s Reservoir Laboratories Manager and Fluids Domain Head, and Advisor Reservoir Fluids and Geochemistry. Since joining Schulmberger in 2010, Artur has held technical management positions and is presently managing 27 rock and fluids laboratories. His achievements span influencing reorganization and growth of the reservoir fluids business through effective global management, supporting R&D efforts, and establishing aqueous and petroleum geochemistry competence and services. Prior to this he worked 12 years for Shell in various research and management positions around the world, taking post in the USA, the Netherlands and UAE. He was Shell’s Expert in the area of Geochemistry, Fluid Properties and Flow Assurance. Artur holds an MSc and PhD in Geology/Organic Geochemistry and spent 2 years as a Post-Doctoral Assistant at Bristol University, UK. He has authored more than 70 articles and 80 conference abstracts, and been an invited lecturer, organizer and chair of numerous international meetings and symposia. He is currently the Chair of the European Association of Organic Geochemists (EAOG), was SPE Distinguished Lecturer 2011/12 and a member of SPE, AAPG.

  • Corey Steffek

    Cory Steffek is the Managing Director of North American at Saudi Aramco Energy Ventures (SAEV), the corporate venturing subsidiary of Saudi Aramco. He is responsible for identifying technology investments of strategic importance in the areas of: upstream oil & gas; downstream oil & gas and value-added products; renewable energy; energy efficiency and water.

    Before joining SAEV, Cory was in Corporate Development and Strategy at First Solar, where he was responsible for strategic investments and acquisitions with emphasis on new technologies and products. Prior to First Solar, Cory was at the Altira Group, an energy-focused venture capital firm, where he led investments in a broad range of energy technology companies. In addition, he has also held several management roles in product development and engineering at PPG Industries. He holds a PhD in materials chemistry from the University of Michigan and an MBA from The Kellogg School of Management at Northwestern University.

  • University of Tokyo Edge Ventures

    UTEC is an early stage technology focused venture capital firm associated with The University of Tokyo. UTEC was founded in 2004, the year the Japanese National University Reform took place. UTEC currently manages its funds of $175 million in total, investing in seed/early stage start-ups. Having proprietary access to the University’s inventions, UTEC works closely with its researchers as scientific founders to co-found companies, which will contribute to society through business based upon innovations. UTEC has invested in 46 companies with 8 IPO and 7 M&A exits to date. For more information visit www.ut-ec.co.jp.

  • Dr. Daryoosh Vakhshoori

    Daryoosh Vakhshoori is the founder and CEO of Pendar Medical, a company pioneering point-of-care medical devices based on optical technologies. Dr. Vakhshoori is an inventor and veteran of high-tech industry. Leveraging his background in opto-electronics he previously founded several successful companies with a focus on purpose-built-solutions and strong commitment to team-based leadership. His technology breakthroughs have transformed industries from telecommunications, safety and security, pharmaceutical manufacturing and medical device development. In 2002 Dr. Vakhshoori was a founder of Ahura Scientific, a developer of transformative handheld Raman and FTIR instruments used for chemical analysis in the field. Ahura Scientific was acquired by Thermo Fisher Scientific in 2010. Dr. Vakhshoori was also co-founder and vice president of CoreTek, which was acquired by Nortel Networks ($1.4B) in 2000. Dr. Vakhshoori earned his Ph.D. in Quantum Electronics from U.C. Berkeley.

  • Dr. David R. Walt

    David R. Walt is Robinson Professor of Chemistry at Tufts University and is a Howard Hughes Medical Institute Professor. Dr. Walt is the Scientific Founder and a Director of both Illumina Inc. and Quanterix Corp. He has published over 300 scientific papers and holds over 60 patents. He has received numerous national and international awards and honors for his fundamental and applied work in the field of optical sensors and arrays. He is a member of the National Academy of Engineering, a fellow of the American Institute for Medical and Biological Engineering, and a fellow of the American Association for the Advancement of Science.

Subscribe to our newsletter! Click Here to join our monthly newsletter.